FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Breast Cancer Research Centre-Western Australia
Research facility
Location:
Nedlands City, Perth, Australia (AU)
ISNI
: -
Publications
(6)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2,-3, and-7 trials: Additional results and key subgroup findings (2021)
Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir NS, Conejo EA, et al.
Conference contribution
Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021)
O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al.
Conference contribution
Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021)
Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al.
Conference contribution
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study (2020)
Fasching P, Beck JT, Chan A, De Laurentiis M, Esteva FJ, Jerusalem G, Neven P, et al.
Journal article
Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) (2020)
Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, et al.
Conference contribution
Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3 (2018)
Fasching P, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, et al.
Conference contribution